Rifka C. Schulman-Rosenbaum

Dr. Rifka C. Schulman-Rosenbaum

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2024 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MPMoshe Phillip
Moshe Phillip
PAPeter Achenbach
Peter Achenbach
AAAnanta Addala
Ananta Addala
AAAnastasia Albanese-O’neill
Anastasia Albanese-O’neill
TBTadej Battelino
Tadej Battelino
LDLinda DiMeglio
Linda DiMeglio
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programs are being increasingly emphasized. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody–positive (IAb+) children and adults who are at risk for (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in nonspecialized settings. To inform this monitoring, JDRF, in conjunction with international experts and societies, developed consensus guidance. Broad advice from this guidance includes the following: 1) partnerships should be fostered between endocrinologists and primary care providers to care for people who are IAb+; 2) when people who are IAb+ are initially identified, there is a need for confirmation using a second sample; 3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; 4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; 5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and 6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasizes significant unmet needs for further research on early-stage type 1 diabetes to increase the rigor of future recommendations and inform clinical care.

24 June 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
MPMoshe Phillip
Moshe Phillip
PAPeter Achenbach
Peter Achenbach
AAAnanta Addala
Ananta Addala
AAAnastasia Albanese-O’nEill
Anastasia Albanese-O’nEill
TBTadej Battelino
Tadej Battelino
LDLinda DiMeglio
Linda DiMeglio
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programmes are being increasingly emphasised. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb+) children and adults who are at risk of (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in non-specialised settings. To inform this monitoring, JDRF in conjunction with international experts and societies developed consensus guidance. Broad advice from this guidance includes the following: (1) partnerships should be fostered between endocrinologists and primary-care providers to care for people who are IAb+; (2) when people who are IAb+ are initially identified there is a need for confirmation using a second sample; (3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; (4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; (5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and (6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasises significant unmet needs for further research on early-stage type 1 diabetes to increase the rigour of future recommendations and inform clinical care. Graphical Abstract

2 April 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
SLSteven B Leichter
Steven B Leichter
JFJamie Felton
Jamie Felton
CRCristy Geno Rasmussen
Cristy Geno Rasmussen
PRPatrick Rizzuto
Patrick Rizzuto
NBNatalie Bellini
Natalie Bellini
RSRifka C. Schulman-Rosenbaum
Rifka C. Schulman-Rosenbaum
Type 1 diabetes (T1D) is an autoimmune disease with 2 presymptomatic stages (stages 1 and 2) that precede its clinical onset (stage 3). The presymptomatic stages of T1D are characterized by circulating autoantibodies that can be reliably detected by autoantibody screening panels. Identifying people in the presymptomatic stages of T1D can allow for monitoring and prevention of diabetic ketoacidosis. A disease-modifying therapy that has been shown to delay onset of stage 3 T1D is now also available for individuals with stage 2 disease, highlighting the importance of early detection. This intervention may delay the onset of stage 3 T1D. Updated guidance and protocols are needed to integrate autoantibody screening into standard practice. This report provides guidance for endocrinology providers on establishing clinical autoantibody screening programs within their practices, institutions, healthcare networks, and/or communities. Key steps include nominating a champion for the program, building a team to implement screening, and motivating other providers to participate. Implementation of screening requires standardizing several steps in the screening process, including communicating with individuals at risk, integrating screening into existing workflows, and streamlining logistics such as ordering and coding for autoantibody panels. Providers must have a plan to interpret and communicate results and to ensure that individuals may be appropriately followed in the future. Here, common barriers to screening are addressed, and practical solutions to facilitate the adoption and success of screening initiatives are offered.

10 December 2023 in Endocrine Practice
Verified
Journal Article
Closed access
BCBenjamin Cohen
Benjamin Cohen
YHYael Tobi Harris
Yael Tobi Harris
RSRifka C. Schulman-Rosenbaum
Rifka C. Schulman-Rosenbaum

15 March 2024 in Diabetes Spectrum
Verified
Journal Article
Closed access
PDF file
MVMatthew Verdone
Matthew Verdone
JBJonathan Bauman
Jonathan Bauman
EIEsben Iversen
Esben Iversen
RSRifka C. Schulman-Rosenbaum
Rifka C. Schulman-Rosenbaum
AAAnthony Antonacci
Anthony Antonacci
JMJoseph Marino
Joseph Marino
Matthew Verdone, Jonathan Bauman, Esben Iversen, Rifka Schulman-Rosenbaum, Anthony Antonacci, Sabatino Leffe, Joseph Simpson, Yael Tobi Harris, Joseph Marino; N

1 November 2021 in Endocrine Practice
Verified
Journal Article
Closed access
RSRifka C. Schulman-Rosenbaum
Rifka C. Schulman-Rosenbaum
NHNina Hadzibabic
Nina Hadzibabic
KCKatherine Cuan
Katherine Cuan
DJDonna Jornsay
Donna Jornsay
EWElissa Wolff
Elissa Wolff
RSRobert A. Silverman
Robert A. Silverman